# Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

> **NCT02028884** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 85 (actual)

## Conditions studied

- Neuromyelitis Optica (NMO)
- NMO Spectrum Disorder (NMOSD)

## Interventions

- **DRUG:** Satralizumab
- **DRUG:** Placebo
- **DRUG:** Baseline Treatment

## Key facts

- **NCT ID:** NCT02028884
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-20
- **Primary completion:** 2018-06-06
- **Final completion:** 2021-12-23
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-04-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02028884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02028884, "Efficacy and Safety Study of Satralizumab (SA237) as Add-on Therapy to Treat Participants With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02028884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*